64 related articles for article (PubMed ID: 8135497)
41. [Possible intervention of glucagon in the genesis of various primary hyperlipemias].
Velasco Domínguez R; Jover E; Rodríguez F; Velasco Alonso R; Marañón A
Rev Clin Esp; 1984 Aug 15-31; 174(3-4):115-8. PubMed ID: 6515072
[No Abstract] [Full Text] [Related]
42. [Effects of the administration of the pancreatic hyperglycemic-glycogenolytic factor (HGF) and of glucose on growth of hypophysioprivic rat].
DE BASTIANI G; PERISSINOTTO B
Chir Organi Mov; 1958; 45(4):269-72. PubMed ID: 13547320
[No Abstract] [Full Text] [Related]
43. Increased serum levels of betatrophin in pancreatic cancer-associated diabetes.
Susanto H; Liu TY; Chen CC; Purnomo JD; Chen SF; Wang CH
Oncotarget; 2016 Jul; 7(27):42330-42339. PubMed ID: 27276680
[TBL] [Abstract][Full Text] [Related]
44. Diabetes and pancreatic cancer.
Li D
Mol Carcinog; 2012 Jan; 51(1):64-74. PubMed ID: 22162232
[TBL] [Abstract][Full Text] [Related]
45. Alteration of the Langerhans islets in pancreatic cancer patients.
Schmied BM; Ulrich AB; Matsuzaki H; Li C; Friess H; Böchler MW; Andron-Sandberg A; Adrian TE; Pour PM
Int J Pancreatol; 2000 Dec; 28(3):187-97. PubMed ID: 11373056
[TBL] [Abstract][Full Text] [Related]
46. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines.
Wang F; Larsson J; Abdiu A; Gasslander T; Westermark P; Adrian TE; Permert J
Int J Pancreatol; 1997 Apr; 21(2):157-64. PubMed ID: 9209957
[TBL] [Abstract][Full Text] [Related]
47. The role of Langerhans islets in exocrine pancreatic cancer.
Pour PM
Int J Pancreatol; 1995 Jun; 17(3):217-23. PubMed ID: 7642968
[No Abstract] [Full Text] [Related]
48. Diabetes mellitus secondary to chronic pancreatitis.
Larsen S
Dan Med Bull; 1993 Apr; 40(2):153-62. PubMed ID: 8495594
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
50. [Behavior of plasma insulin, C-peptide and glucagon in normal subjects and in patients with liver cirrhosis].
Gragnoli G; Tanganelli I; Signorini AM
Boll Soc Ital Biol Sper; 1980 Jan; 56(1):69-75. PubMed ID: 7002168
[TBL] [Abstract][Full Text] [Related]
51. Diabetes mellitus in pancreatic cancer follow-up.
Fogar P; Pasquali C; Basso D; Sperti C; Panozzo MP; Tessari G; D'Angeli F; Del Favero G; Plebani M
Anticancer Res; 1994; 14(6B):2827-30. PubMed ID: 7532931
[TBL] [Abstract][Full Text] [Related]
52. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
[TBL] [Abstract][Full Text] [Related]
53. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer.
Nakamori S; Ishikawa O; Ohigashi H; Sasakuma F; Shimizu T; Nakaizumi A; Furukawa H; Sasaki Y; Imaoka S
Hepatogastroenterology; 1999; 46(25):16-24. PubMed ID: 10228759
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of measuring serum c-peptide before and after glucagon injection].
Kan Y; Chi Z
Zhonghua Yi Xue Za Zhi; 1991 Jan; 71(1):16-7, 4. PubMed ID: 1850647
[TBL] [Abstract][Full Text] [Related]
55. C-peptide pattern in patients with pancreatic cancer.
Fogar P; Basso D; Panozzo MP; Del Favero G; Briani G; Fabris C; D'Angeli F; Meggiato T; Ferrara C; Plebani M
Anticancer Res; 1993; 13(6B):2577-80. PubMed ID: 8135497
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
